EGFR and neoplasm: Given that we found a rare EGFRT790M subclone in the polyclonal resistant tumor, we next explored whether BRAFV600E expression could promote resistance to EGFR TKI treatment in H1975 human lung adenocarcinoma cells that endogenously express EGFRT790M and EGFRL858R.